Novo Nordisk A/S (NVO)
Company Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides insulin pens, growth hormone pens, and injection needles.
In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space.
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Country | DK |
IPO Date | Apr 30, 1981 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 76,302 |
CEO | Lars Fruergaard Jorgensen |
Contact Details
Address: Novo Alle 1 Bagsvaerd, DK | |
Website | https://www.novonordisk.com |
Stock Details
Ticker Symbol | NVO |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000353278 |
CUSIP Number | 670100205 |
ISIN Number | US6701002056 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Lars Fruergaard Jorgensen | President, Chief Executive Officer & Member of Management Board |
Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board |
Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board |
David S. Moore | Executive Vice President of US Operations & Global Business Development and Member of Management Board |
Dr. Marcus Schindler Ph.D. | EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board |
Dr. Martin Holst Lange | Executive Vice President of Development & Member of the Management Board |
Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board |
Ludovic Helfgott | Executive Vice President of Rare Disease & Member of Management Board |
Maziar Mike Doustdar | Executive Vice President of International Operations & Member of the Management Board |
Tania Sabroe | Executive Vice President of Global People & Organisation and Member of Management Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 10, 2025 | 6-K | Filing |
Feb 27, 2025 | 6-K | Filing |
Feb 10, 2025 | IRANNOTICE | Filing |
Feb 07, 2025 | 6-K | Filing |
Feb 06, 2025 | 6-K | Filing |
Feb 05, 2025 | 6-K | Filing |
Feb 05, 2025 | 6-K | Filing |
Feb 05, 2025 | 20-F | Filing |
Feb 05, 2025 | 6-K | Filing |
Feb 04, 2025 | 6-K | Filing |